92 related articles for article (PubMed ID: 28551657)
1. Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.
Wang W; Zhong W; Chen C; Meng Q; Wei J
Anticancer Res; 2017 Jun; 37(6):3151-3155. PubMed ID: 28551657
[TBL] [Abstract][Full Text] [Related]
2. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.
Wang W; Guan S; Sun S; Jin Y; Lee KH; Chen Y; Wei J
Tumour Biol; 2014 May; 35(5):4901-5. PubMed ID: 24453033
[TBL] [Abstract][Full Text] [Related]
3. Increased Levels of Circulating Anti-ANXA1 IgG Antibody in Patients with Non-Small Cell Lung Cancer.
Liang T; Han Z; Zhao H; Zhang X; Wang Y
Clin Lab; 2018 Jun; 64(6):895-900. PubMed ID: 29945332
[TBL] [Abstract][Full Text] [Related]
4. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
[TBL] [Abstract][Full Text] [Related]
5. Investigation of circulating antibodies to ANXA1 in breast cancer.
Huang Y; Zhang C; Chen C; Sun S; Zheng H; Wan S; Meng Q; Chen Y; Wei J
Tumour Biol; 2015 Feb; 36(2):1233-6. PubMed ID: 25344217
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.
Zhang C; Ye L; Guan S; Jin S; Wang W; Sun S; Lee KH; Wei J; Liu B
Tumour Biol; 2014 Mar; 35(3):2047-51. PubMed ID: 24122232
[TBL] [Abstract][Full Text] [Related]
7. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.
Brichory FM; Misek DE; Yim AM; Krause MC; Giordano TJ; Beer DG; Hanash SM
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9824-9. PubMed ID: 11504947
[TBL] [Abstract][Full Text] [Related]
8. FOXP3 autoantibody as a potential early prognostic serum biomarker in patients with cervical cancer.
Xu S; Huangfu M; Jia X; Song X; Sun B; Lee KH; Liu L; Sun S
Int J Clin Oncol; 2015 Oct; 20(5):982-8. PubMed ID: 25681877
[TBL] [Abstract][Full Text] [Related]
9. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
[TBL] [Abstract][Full Text] [Related]
10. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer.
Farlow EC; Patel K; Basu S; Lee BS; Kim AW; Coon JS; Faber LP; Bonomi P; Liptay MJ; Borgia JA
Clin Cancer Res; 2010 Jul; 16(13):3452-62. PubMed ID: 20570928
[TBL] [Abstract][Full Text] [Related]
11. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
[TBL] [Abstract][Full Text] [Related]
12. Study of circulating antibodies against CD25 and FOXP3 in breast cancer.
Liu T; Song YN; Shi QY; Liu Y; Bai XN; Pang D
Tumour Biol; 2014 Apr; 35(4):3779-83. PubMed ID: 24347486
[TBL] [Abstract][Full Text] [Related]
13. Biomarker studies abound for early detection of lung cancer.
Brower V
J Natl Cancer Inst; 2009 Jan; 101(1):11-3. PubMed ID: 19116384
[No Abstract] [Full Text] [Related]
14. Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer.
Tantai J; Hu D; Yang Y; Geng J
Int J Clin Exp Pathol; 2015; 8(7):7887-95. PubMed ID: 26339353
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer.
Liu S; Zhang X; Jiang Q; Liang T
FEBS Open Bio; 2020 Jul; 10(7):1288-1294. PubMed ID: 32392378
[TBL] [Abstract][Full Text] [Related]
16. Further study of circulating IgG antibodies to CD25-derived peptide antigens in nonsmall cell lung cancer.
Chen C; Wang W; Meng Q; Wu N; Wei J
FEBS Open Bio; 2016 Mar; 6(3):211-5. PubMed ID: 27047749
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of ANXA1 suppresses the biological behavior of human NSCLC cells in vitro.
Fang Y; Guan X; Cai T; Long J; Wang H; Xie X; Zhang Y
Mol Med Rep; 2016 May; 13(5):3858-66. PubMed ID: 27035116
[TBL] [Abstract][Full Text] [Related]
18. Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer.
Chen SS; Li K; Wu J; Peng ZY; Wang ZD; Wang JC; Xu CW; Zhu CL; Li BC; Ren H; Tang SC; Sun X
J Cancer Res Clin Oncol; 2021 Jan; 147(1):223-233. PubMed ID: 32691153
[TBL] [Abstract][Full Text] [Related]
19. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells.
Tao H; Mimura Y; Aoe K; Kobayashi S; Yamamoto H; Matsuda E; Okabe K; Matsumoto T; Sugi K; Ueoka H
Lung Cancer; 2012 Jan; 75(1):95-101. PubMed ID: 21719142
[TBL] [Abstract][Full Text] [Related]
20. Rethinking Autoantibody Signature Panels for Cancer Diagnosis.
Campa MJ; Gottlin EB; Herndon JE; Patz EF
J Thorac Oncol; 2017 Jun; 12(6):1011-1014. PubMed ID: 28126538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
